{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:12:15Z","timestamp":1791396735694,"version":"4.3.3"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This study aimed to evaluate the efficacy and safety of lumateperone in treating bipolar disorder and schizophrenia. A comprehensive literature search was conducted across multiple databases and websites from inception to July 16, 2024, to identify both published and unpublished randomized controlled trials (RCTs). Meta-analyses were performed using random-effects or fixed-effects models depending on statistical heterogeneity. Relative risks (RRs) or standardized mean differences (SMDs) with 95% confidence intervals (CIs) were used to summarize the effects. Out of 931 records screened, 7 RCTs (four focusing on bipolar depression and 3 on schizophrenia) were eligible for inclusion. Lumateperone was efficacious in reducing depressive symptoms in bipolar depression (SMDs = \u22120.36, 95% CI: \u2212.59 to \u2212.13). In treating schizophrenia, lumateperone exhibited a lower combined SMD of -0.14 (95% CI: \u2212.27 to 0, P = .051, I\u00b2 = 49.6%), showing no significant difference from the placebo group, although the P-value approached significance. The lumateperone group showed significantly higher response rates compared with placebo in both bipolar depression (RRs = 1.27, 95% CI = 1.07 to 1.51) and schizophrenia (RRs = 1.44, 95% CI = 1.12 to 1.86). Common treatment-emergent adverse events included somnolence, dry mouth, dizziness, nausea, and headache (RRs = 1.30 to 3.29). Importantly, lumateperone did not significantly increase extrapyramidal symptoms (EPS, RRs = 1.46, 95% CI = .84 to 2.53). Lumateperone is effective in treating bipolar depression but does not significantly reduce symptom severity in schizophrenia. It has a favorable safety and tolerability profile. However, caution is warranted in interpreting these findings due to the limited number of studies included.<\/jats:p>","DOI":"10.1093\/ijnp\/pyae052","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T04:18:40Z","timestamp":1730348320000},"source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of lumateperone for bipolar depression and schizophrenia: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"27","author":[{"given":"Hanrui","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha 410011, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewen","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, First Affiliated Hospital of Kunming Medical University , Kunming 650032, Yunnan ,","place":["China"]},{"name":"The Third People\u2019s Hospital of Qujing , Qujing 655000, Yunnan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, First Affiliated Hospital of Kunming Medical University , Kunming 650032, Yunnan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha 410011, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha 410011, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine , Hangzhou 310016, Zhejiang ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyi","family":"Li","sequence":"additional","affiliation":[{"name":"The Third People\u2019s Hospital of Qujing , Qujing 655000, Yunnan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha 410011, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixue","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha 410011, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha 410011, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7730-2248","authenticated-orcid":false,"given":"Tieqiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha 410011, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zejun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University , Changsha 410011, Hunan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"key":"2024112114041002100_CIT0001","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1176\/appi.ajp.2021.20091339","article-title":"Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or Bipolar II disorder: a phase 3 randomized placebo-controlled trial","volume":"178","author":"Calabrese","year":"2021","journal-title":"Am J Psychiatry"},{"key":"2024112114041002100_CIT0002","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra1906193","article-title":"Bipolar disorder","volume":"383","author":"Carvalho","year":"2020","journal-title":"N Engl J Med"},{"key":"2024112114041002100_CIT0003","doi-asserted-by":"publisher","first-page":"102294","DOI":"10.1016\/j.eclinm.2023.102294","article-title":"Life expectancy and years of potential life lost in people with mental disorders: a systematic review and meta-analysis","volume":"65","author":"Chan","year":"2023","journal-title":"E Clinical Medicine"},{"key":"2024112114041002100_CIT0004","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"Correll","year":"2010","journal-title":"Eur Psychiatry"},{"key":"2024112114041002100_CIT0005","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"key":"2024112114041002100_CIT0006","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"key":"2024112114041002100_CIT0007","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and safety of lumateperone for treatment of schizophrenia: a Randomized Clinical Trial","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"2024112114041002100_CIT0008","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2024112114041002100_CIT0009","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/14737175.2016.1174577","article-title":"ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes","volume":"16","author":"Davis","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"2024112114041002100_CIT0010","author":"FDA (Food and Drug Administration)","year":"2018"},{"key":"2024112114041002100_CIT0011","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"2024112114041002100_CIT0012","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","journal-title":"Lancet"},{"key":"2024112114041002100_CIT0013","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"GBD 2021 Causes of Death Collaborators","year":"2024","journal-title":"Lancet"},{"key":"2024112114041002100_CIT0014","doi-asserted-by":"publisher","first-page":"e073591","DOI":"10.1136\/bmj-2022-073591","article-title":"Diagnosis and management of bipolar disorders","volume":"381","author":"Goes","year":"2023","journal-title":"BMJ"},{"key":"2024112114041002100_CIT0015","first-page":"18","article-title":"Using the Positive and Negative Syndrome Scale (PANSS) to define different domains of negative symptoms: prediction of everyday functioning by impairments in emotional expression and emotional experience","volume":"14","author":"Harvey","year":"2017","journal-title":"Innov Clin Neurosci"},{"key":"2024112114041002100_CIT0016","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"2024112114041002100_CIT0017","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11920-022-01344-1","article-title":"Lumateperone for the treatment of adults with schizophrenia: a systematic review","volume":"24","author":"Jawad","year":"2022","journal-title":"Curr Psychiatry Rep"},{"key":"2024112114041002100_CIT0018","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"key":"2024112114041002100_CIT0019","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"key":"2024112114041002100_CIT0020","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s40265-023-01872-x","article-title":"New pharmacologic approaches to the treatment of bipolar depression","volume":"83","author":"Keramatian","year":"2023","journal-title":"Drugs"},{"key":"2024112114041002100_CIT0021","doi-asserted-by":"publisher","first-page":"102581","DOI":"10.1016\/j.eclinm.2024.102581","article-title":"Effect of antipsychotics and mood stabilisers on metabolism in bipolar disorder: a network meta-analysis of randomised-controlled trials","volume":"71","author":"Kong","year":"2024","journal-title":"E Clinical Medicine"},{"key":"2024112114041002100_CIT0022","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2147\/NDT.S47711","article-title":"Time to relapse and remission of bipolar disorder: findings from a 1-year prospective study in Thailand","volume":"9","author":"Leelahanaj","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2024112114041002100_CIT0023","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1192\/j.eurpsy.2024.25","article-title":"Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis","volume":"67","author":"Li","year":"2024","journal-title":"Eur Psychiatry"},{"key":"2024112114041002100_CIT0024","doi-asserted-by":"publisher","first-page":"115640","DOI":"10.1016\/j.psychres.2023.115640","article-title":"Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis","volume":"331","author":"Li","year":"2024","journal-title":"Psychiatry Res"},{"key":"2024112114041002100_CIT0025","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the Treatment of Schizophrenia: a 4-Week Randomized, Double-Blind, Controlled Trial","volume":"79","author":"Lieberman","year":"2016","journal-title":"Biol Psychiatry"},{"key":"2024112114041002100_CIT0026","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.neubiorev.2021.11.032","article-title":"New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics","volume":"132","author":"Lobo","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"2024112114041002100_CIT0027","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1176\/appi.ajp.2013.13070985","article-title":"Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am J Psychiatry"},{"key":"2024112114041002100_CIT0028","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/0004867420979353","article-title":"The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders","volume":"55","author":"Malhi","year":"2021","journal-title":"Aust N Z J Psychiatry"},{"key":"2024112114041002100_CIT0029","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia-An overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"2024112114041002100_CIT0030","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/S0140-6736(20)31544-0","article-title":"Bipolar disorders","volume":"396","author":"McIntyre","year":"2020","journal-title":"Lancet"},{"key":"2024112114041002100_CIT0031","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2024112114041002100_CIT0032","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40261-021-01000-1","article-title":"Second-generation antipsychotic drugs for patients with schizophrenia: systematic literature review and meta-analysis of metabolic and cardiovascular side effects","volume":"41","author":"Rognoni","year":"2021","journal-title":"Clin Drug Investig"},{"key":"2024112114041002100_CIT0033","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.euroneuro.2019.07.132","article-title":"Genes, biomarkers, and clinical features associated with the course of bipolar disorder","volume":"29","author":"Smedler","year":"2019","journal-title":"Eur Neuropsychopharmacol"},{"key":"2024112114041002100_CIT0034","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission","volume":"232","author":"Snyder","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"2024112114041002100_CIT0035","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"2024112114041002100_CIT0036","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/wps.20765","article-title":"Safety of 80 antidepressants, antipsychotics, anti-attention-deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects","volume":"19","author":"Solmi","year":"2020","journal-title":"World Psychiatry"},{"key":"2024112114041002100_CIT0037","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.4088\/JCP.12m08049","article-title":"Recovery from multiple episodes of bipolar I depression","volume":"74","author":"Solomon","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"2024112114041002100_CIT0038","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/bdi.13310","article-title":"Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: results from a randomized placebo-controlled clinical trial","volume":"25","author":"Suppes","year":"2023","journal-title":"Bipolar Disord"},{"key":"2024112114041002100_CIT0039","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.euroneuro.2022.06.009","article-title":"Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: a dopamine D(1) receptor dependent mechanism","volume":"62","author":"Titulaer","year":"2022","journal-title":"Eur Neuropsychopharmacol"},{"key":"2024112114041002100_CIT0040","doi-asserted-by":"publisher","first-page":"S351","DOI":"10.1093\/schbul\/sbz020.662","article-title":"S117. Favorable long-term safety profile of Lumateperone Iiti-007): Results from a 12 month open label safety study for lumateperone in patients with stable symptoms of Schizophrenia","volume":"45","author":"Vanover","year":"2019","journal-title":"Schizophr Bull"},{"key":"2024112114041002100_CIT0041","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41386-018-0251-1","article-title":"Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia","volume":"44","author":"Vanover","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"2024112114041002100_CIT0042","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/14656566.2019.1695778","article-title":"An evaluation of lumateperone tosylate for the treatment of schizophrenia","volume":"21","author":"Vyas","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"2024112114041002100_CIT0043","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"key":"2024112114041002100_CIT0044","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S2215-0366(23)00199-2","article-title":"Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis","volume":"10","author":"Yildiz","year":"2023","journal-title":"Lancet Psychiatry"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyae052\/60304881\/pyae052.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyae052\/60778436\/pyae052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyae052\/60778436\/pyae052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T14:04:20Z","timestamp":1732197860000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyae052\/7863712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyae052","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,11,1]]},"article-number":"pyae052"}}